Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK’s NICE Backs Interim Funding For 14-Day Ambulatory Heart Monitoring Tech

Executive Summary

Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.

You may also be interested in...



Reimbursement For Long-Term Cardiac Monitoring Remains Uncertain, iRhythm Reports

Local Medicare carrier Novitas met with monitoring companies to discuss rates for long-term ECG monitoring, but no final decision on recently proposed rate cuts has been reached, iRhythm reported.

Cardiac Monitoring Companies Fight Medicare Reimbursement Cut By Novitas

Medicare carrier Novitas has proposed to cut reimbursement for long-term electrocardiogram monitoring, which could be a major headache for companies like iRhythm.

AI Tops The Tech Priorities For UK NHS With New Govt Funding Pledge

With health care in the UK being increasingly restructured around digital delivery, bodies like the new NHSX, NHS Digital and the forthcoming Digital Innovation Hubs will be in the forefront of health-care policy-making at the national level. A new government funding pledge has underlined the importance of taking the opportunities that artificial intelligence, machine learning and genomic medicine offer in health care.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT143139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel